Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity

International Journal of Nanomedicine

Volumn 9, Issue , 2014, Pages 4829-4846

  Yuan, Qing ^a   Han, Jing ^a,b   Cong, Wenshu ^a   Ge, Ying ^c   Ma, Dandan ^a,c   Dai, Zhaoxia ^c   Li, Yaping ^d   Bi, Xiaolin ^a,c  

^a INSTITUTE OF HIGH ENERGY PHYSICS   (China)

^b ANHUI UNIVERSITY   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Breast cancer; Docetaxel; Docetaxel loaded solid lipid nanoparticles; Toxicity

Indexed keywords

DOCETAXEL; MESSENGER RNA; SOLID LIPID NANOPARTICLE; ANTINEOPLASTIC AGENT; DRUG CARRIER; LIPID; NANOPARTICLE; TAXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG CARRIERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPIDS; MICE; MICE, NUDE; NANOPARTICLES; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928140724     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S70919     Document Type: Article

References (39)

1. Gueritte-Voegelein F, Guenard D, Dubois J, Wahl A, Potier P. [Chemical and biological studies on Taxol (paclitaxel) and Taxotere (docetaxel), new antineoplastic agents]. J Pharm Belg. 1994; 49(3): 193-205. French.
2. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005; 6(4): 229-239.
3. Saloustros E, Georgoulias V. Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2008; 8(8): 1207-1222.
4. Saloustros E, Mavroudis D, Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother. 2008; 9(15): 2603-2616.
5. Aapro M. The scientific rationale for developing taxoids. Anticancer Drugs. 1996; 7(Suppl 2): 33-36.
6. Canales A, Rodriguez-Salarichs J, Trigili C, et al. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach. ACS Chem Biol. 2011; 6(8): 789-799.
7. Hernandez-Vargas H, Palacios J, Moreno-Bueno G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene. 2007; 26(20): 2902-2913.
8. Berchem GJ, Bosseler M, Mine N, Avalosse B. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest, and phosphorylates bcl-2. Anticancer Res. 1999; 19(1A): 535-540.
9. Kuppens IE. Current state of the art of new tubulin inhibitors in the clinic. Curr Clin Pharmacol. 2006; 1(1): 57-70.
10. Baker J, Ajani J, Scotte F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009; 13(1): 49-59.
11. Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer. 2003; 89(Suppl 3): S9-S15.
12. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol. 2006; 17(5): 735-749.
13. Weiszhar Z, Czucz J, Revesz C, Rosivall L, Szebeni J, Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80, and Tween-20. Eur J Pharm Sci. 2012; 45(4): 492-498.
14. Karve S, Werner ME, Sukumar R, et al. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci U S A. 2012; 109(21): 8230-8235.
15. Hwang HY, Kim IS, Kwon IC, Kim YH. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2008; 128(1): 23-31.
16. Xu Z, Chen L, Gu W, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009; 30(2): 226-232.
17. Esmaeili F, Dinarvand R, Ghahremani MH, Ostad SN, Esmaily H, Atyabi F. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles. Anticancer Drugs. 2010; 21(1): 43-52.
18. Yanasarn N, Sloat BR, Cui Z. Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. Int J Pharm. 2009; 379(1): 174-180.
19. Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. Preparation, characterization, cytotoxicity, and pharmacokinetics of liposomes containing docetaxel. J Control Release. 2003; 91(3): 417-429.
20. Liang G, Jia-Bi Z, Fei X, Bin N. Preparation, characterization, and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes. J Pharm Pharmacol. 2007; 59(5): 661-667.
21. Zhai G, Wu J, Xiang G, et al. Preparation, characterization, and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J Nanosci Nanotechnol. 2009; 9(3): 2155-2161.
22. Werner ME, Copp JA, Karve S, et al. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano. 2011; 5(11): 8990-8998.
23. Elsabahy M, Perron ME, Bertrand N, Yu GE, Leroux JC. Solubilization of docetaxel in poly(ethylene oxide)-block-poly(butylene/styrene oxide) micelles. Biomacromolecules. 2007; 8(7): 2250-2257.
24. Shin HC, Alani AW, Rao DA, Rockich NC, Kwon GS. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release. 2009; 140(3): 294-300.
25. Mu CF, Balakrishnan P, Cui FD, et al. The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials. 2010; 31(8): 2371-2379.
26. Liu J, Zahedi P, Zeng F, Allen C. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J Pharm Sci. 2008; 97(8): 3274-3290.
27. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006; 103(16): 6315-6320.
28. Zheng D, Li D, Lu X, Feng Z. Enhanced antitumor efficiency of docetaxel-loaded nanoparticles in a human ovarian xenograft model with lower systemic toxicities by intratumoral delivery. Oncol Rep. 2010; 23(3): 717-724.
29. Gao Y, Yang R, Zhang Z, Chen L, Sun Z, Li Y. Solid lipid nanoparticles reduce systemic toxicity of docetaxel: performance and mechanism in animal. Nanotoxicology. 2011; 5(4): 636-649.
30. Zhang P, Chen L, Zhang Z, Lin L, Li Y. Pharmacokinetics in rats and efficacy in murine ovarian cancer model for solid lipid nanoparticles loading docetaxel. J Nanosci Nanotechnol. 2010; 10(11): 7541-7544.
31. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90.
32. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12): 2893-2917.
33. Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist. 2004; 9(Suppl 2): 24-32.
34. Sandberg R, Larsson O. Improved precision and accuracy for microarrays using updated probe set definitions. BMC Bioinformatics. 2007; 8: 48.
35. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3: Article3.
36. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5): P3.
37. Kong L, Yuan Q, Zhu H, et al. The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. Biomaterials. 2011; 32(27): 6515-6522.
38. Song H, Vita M, Sallam H, et al. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro. Cancer Chemother Pharmacol. 2007; 60(6): 841-849.
39. Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009; 26(6): 523-580.